Navigation Links
Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent
Date:12/14/2010

used on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.<
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Announces Update Call Regarding Vial Problems
2. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
3. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
4. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
5. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
6. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
7. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
8. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... CITY, Calif., Dec. 18, 2014 Capnia, ... the development of medical diagnostics based on its ... gas flow, today announced financial results for the ... 2014. "Following the completion of our ... positioned to maximize the recently initiated CoSense® commercial ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last month,s ... site now known as the leading online black market ... explosive growth in its offering of drugs and other ... show the takedowns did succeed in lowering the numbers ... review of the markets in August. But some new ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
... HAMBURG, Germany, Sept. 20, 2011 Weight and height, ... leader for medical measuring and weighing. Now the company ... system integrating modern medical practices and hospital equipment. The ... problems of precise data capture, transmission and interpretation of ...
... Sept. 20, 2011 Valeant Pharmaceuticals International, Inc. ... existing senior secured credit facilities of its wholly ... facilities are guaranteed by the Company.  The proposed ... to consist of a $200 million revolving facility ...
Cached Medicine Technology:seca 360 wireless - The New Era of Measuring and Weighing 2Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2
(Date:12/21/2014)... AlignLife of Norton Shores is spreading ... same time helping people get their health back. Mission ... to serving those persons in Muskegon County who are unable ... quality of life. Dr. Michael Rykse wanted to do a ... community and he knew he found that when he heard ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is a professional ... . The business has recently shown its new engineered ... all its bamboo flooring models. , BambooIndustry.com’s customers come ... Asia and more. According to the CEO of the ... very fast in the past few years, and the ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its 2015 collection ... big discounts on all of its special occasion dresses & ... a perfect wedding gown. If you have no idea of ... LunaDress. Many different wedding dress styles and our dress experts ... enjoy the current special offer, up to 80% off," the ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
Breaking Medicine News(10 mins):Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
... Low-Power Design for Innovative Medical ... ... SNPS ), a world leader in software and IP for semiconductor design,and ... signal processor (DSP) chipset for hearing-aid,devices using Synopsys, IC Compiler design planning ...
... football players, but they aren,t necessarily dangerous, experts say ... players are twice as likely as whites to have ... that doesn,t mean they are at greater risk of ... 2,000 athletes, done at the National Football League Invitational ...
... TOWSON, Md., June 2 Katzen Eye Group ... Refractive Therapy, Paragon CRT.,Paragon CRT temporarily corrects nearsightedness ... dedication to the health of their patients, Katzen ... the latest,advancements in vision care. Paragon CRT is ...
... and Grammy Award-Winning Music,Icons in Cancer Awareness Campaign, ... an estimated 260,000 women will be diagnosed with breast, ... 69,000,women will die from these diseases. In response, a ... to communicate a very,important message to all American women: ...
... early psychotic symptoms, researchers say , , MONDAY, June 2 ... long time can develop abnormalities in their brains, Australian ... marijuana use is associated with a wide range of ... harmless and should be legalized, the researchers noted. , ...
... UT Southwestern Medical Center physician and other researchers have ... of a patient being cancer free 12 years after ... a nomogram, uses tumor and patient characteristics to maximize ... the cancer,s return can help clinicians counsel patients and ...
Cached Medicine News:Health News:Oticon Tapes Out Innovative Hearing-Aid DSP Using Synopsys IC Compiler 2Health News:Oticon Tapes Out Innovative Hearing-Aid DSP Using Synopsys IC Compiler 3Health News:Black Athletes' Hearts May Differ From Those of Whites 2Health News:Black Athletes' Hearts May Differ From Those of Whites 3Health News:Katzen Eye Group Announces a New Option in Vision Correction Technology for Patients 2Health News:Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 2Health News:Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 3Health News:Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy 4Health News:Marijuana May Shrink Parts of the Brain 2Health News:Marijuana May Shrink Parts of the Brain 3Health News:New model predicts whether patients will be free of renal cancer 12 years after initial treatment 2